Acute neuritis due to anti-myelin oligodendrocyte glycoprotein associated disease (MOGAD) improves without acute treatments, while myelitis due to MOGAD improves less if not treated, according to a ...

In patients with SCD, although the lifespan of their reticulocytes remains unknown, the number of immature reticulocytes is on the rise. Research has shown that reticulocytosis can predict morbidity ...

Clonal dynamics varied across patients with advanced SM, with some subclones persisting despite treatment. Subclonal architecture analysis showed varying clonal dynamics, with some subclones ...

No temporarily associated relapses were observed in 25 patients vaccinated or boostered against meningococcal disease during ECU therapy. Eculizumab treatment reduces annualized attack rate (AAR) and ...

For SLE-related GBS and CIDP, treatment for primary disease should also be initiated in addition to first-line therapy for GBS and CIDP. Systemic lupus erythematosus (SLE) may manifest as chronic ...

In terms of the safety profile, 40 patients (37%) experienced injection site reactions as the most frequent adverse event. Real-world data confirms the safety profile of IgPro20 for patients with ...

The researchers said that blood samples are ready for analysis and that preliminary results will be presented soon. The plan of a case-control study that will investigate the potential role of the ...

Of the two entities, only NMOSD involved the brain, with 35.7% of the patients presenting with brain lesions. Spinal cord and brain imaging could narrow differential diagnosis for patients with ...

Headache was the most common treatment-emergent adverse event in a trial of rozanolixizumab for generalized MG. Change in Myasthenia Gravis Activities of Daily Living score averaged −2.1 with ...

CIDP tremor stopped following ventral intermediate nucleus of thalamus ablation with high-intensity focused ultrasound. The ablation of the ventral intermediate nucleus of the thalamus with ...

Working with Friedreich ataxia (FA) is not part of my daily schedule. Although there are some things that I can easily do, there are many other things that would prevent me from completing the ...

I have been fighting the battle of living with Pompe disease but I am challenging what doctors define as possible with this disease. I live in South Africa with late-onset Pompe and I have been doing ...